PHARMACEUTICAL 2017
Assertio Therapeutics Inc Rank 39 of 292


The relative strengths and weaknesses of Assertio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Assertio Therapeutics Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by $145 \%$ points.The greatest weakness of Assertio Therapeutics Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 28\% points.

The company's Economic Capital Ratio, given in the ranking table, is $224 \%$, being $221 \%$ points above the market average of 2.9\%.

| Input Variable | Value in <br> 1000 USD |
| :--- | ---: |
| Assets, Current | 306,204 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 902,149 |
| Liabilities, Current | 227,242 |
| Liabilities, Non-Current | 0 |
| Other Assets | 3,458 |
| Other Compr. Net Income | 35 |
| Other Expenses | $-89,011$ |
| Other Liabilities | 455,897 |
| Other Net Income | 15,526 |
| Other Revenues | 32,631 |
| Property and Equipment | 204,498 |
| Research and Development |  |
| Selling, General and Administrative <br> Expense |  |


| Output Variable | Value in <br> $\mathbf{1 0 0 0}$ USD |
| :--- | ---: |
| Assets | $1,225,337$ |
| Liabilities | 227,242 |
| Expenses | 455,606 |
| Revenues | 455,897 |
| Stockholders Equity | 998,095 |
| Net Income | $-88,720$ |
| Comprehensive Net Income | $-88,702$ |
| Economic Capital Ratio | $224 \%$ |

